Eli Lilly and Company (LLY) Stock Analysis
Is LLY a good investment?
Eli Lilly and Company (LLY) has a Plutrex AI rating of 85.0/100 as of October 08, 2026, indicating a Strong Buy consensus. The stock is halal-compliant per AAOIFI standards. Key strength: PEG ratio of 1.32 versus industry average of 4.59 — LLY investors pay 71.2% LESS per unit of long-term growth than peers despite the 41.8% P/E premium; this is the single most important valuation insight confirming LLY is the best growth value in the pharmaceutical sector. Combined with 5-year EPS CAGR of 30.6% (116.8% faster than the industry's 14.09%), the growth-adjusted case is unambiguous.. Main concern: GLP-1 insurance coverage erosion and MFN (Most Favored Nation) pricing pressure: the reported 72%-to-60% coverage trajectory creates simultaneous volume-AND-price risk on the franchise underpinning the 30.6% EPS CAGR. With P/E at 40.39x, each 5% miss in EPS growth likely compresses the multiple by 3-5 turns, creating non-linear downside — this remains the primary structural risk and is UNCHANGED with no new data in either direction in the current news cycle..
Investment Summary
Eli Lilly (LLY) at $1,188.72 remains one of the highest-quality compounders in the S&P 500 and the unambiguous leader in the pharmaceutical sector. The investment thesis is anchored by three interlocking pillars: (1) World-class profitability — gross margin 83.4%, operating margin 54.2% (76% above industry average of 30.74%), net margin 33.53% (99% above industry average of 16.82%), and ROE of 102.4% (303% above the 25.41% industry mean); (2) Elite sustainable growth — 5-year forward EPS CAGR of 30.6% versus industry average of 14.09%, supported by $20.05B annual FCF that validates analyst forecasts with hard cash generation; (3) Growth-adjusted valuation discipline — PEG of 1.32 versus industry average PEG of 4.59, meaning LLY investors pay 71.2% less per unit of long-term growth than the average peer despite the 41.8% P/E premium (40.39x vs. 28.48x industry). Key news developments reinforce the thesis: FDA approval expanding Jaypirca's indication to first-line CLL/SLL (first non-covalent BTK inhibitor with this approval, differentiating on mechanism), Gate Bioscience deal worth $870M+ expanding the discovery pipeline, and the pancreatic cancer drug oncology footprint expansion. The sole analyst consensus target reduction from $1,346.73 to $1,328.33 (-$18.40, -1.4%) is immaterial and does not alter the directional call. Net: Strong Buy at current levels with disciplined entry range.
Key Strengths
- PEG ratio of 1.32 versus industry average of 4.59 — LLY investors pay 71.2% LESS per unit of long-term growth than peers despite the 41.8% P/E premium; this is the single most important valuation insight confirming LLY is the best growth value in the pharmaceutical sector. Combined with 5-year EPS CAGR of 30.6% (116.8% faster than the industry's 14.09%), the growth-adjusted case is unambiguous.
- World-class profitability franchise: operating margin 54.22% (76.4% above industry average), gross margin 83.4% (17% above industry), ROE 102.4% (303% above industry), and $20.05B annual FCF — this cash generation enables simultaneous debt reduction, R&D reinvestment ($7B+), manufacturing capacity build, buybacks, and dividend growth, creating a self-funding growth engine that most peers cannot replicate.
- Expanding multi-indication pipeline with FDA momentum: Jaypirca's first-line CLL/SLL approval (unique mechanism as only non-covalent BTK inhibitor with first-line indication), pancreatic cancer drug approval expanding oncology footprint, Gate Bioscience $870M+ drug discovery deal deepening the pipeline, and the GLP-1 platform's growth opportunity 'beyond weight loss' — all reducing concentration risk in the core GLP-1 franchise while adding incremental revenue streams.
Key Concerns
- GLP-1 insurance coverage erosion and MFN (Most Favored Nation) pricing pressure: the reported 72%-to-60% coverage trajectory creates simultaneous volume-AND-price risk on the franchise underpinning the 30.6% EPS CAGR. With P/E at 40.39x, each 5% miss in EPS growth likely compresses the multiple by 3-5 turns, creating non-linear downside — this remains the primary structural risk and is UNCHANGED with no new data in either direction in the current news cycle.
- Analyst consensus target reduced from $1,346.73 to $1,328.33 (-$18.40, -1.4%), modestly shrinking the upside to 11.7% from current price. While directionally immaterial, the direction of revision combined with the P/E of 40.39x at Debt-to-Equity of 1.41 (66% above industry) creates a dual-compression scenario: any revenue disappointment triggers both downward earnings revisions AND multiple contraction simultaneously, with limited balance sheet cushion (D/E 1.41 vs. industry 0.85) to absorb the shock.
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
LLY's financials represent a near-perfect profile for a mega-cap growth company. Profitability: Gross margin 83.4% reflects patent-protected GLP-1 pricing power; operating margin 54.22% demonstrates extraordinary fixed-cost leverage at scale; net margin 33.53% confirms that one-third of every revenue dollar flows to bottom line after all obligations; ROE of 102.4% indicates the company generates more than its entire equity base annually in earnings. Growth: Revenue grew 47.7% YoY, validating the GLP-1 commercial ramp. Trailing EPS growth of 113.5% (driven partly by buybacks and operating leverage) creates a high comparison base, but forward estimates of 28.2% next-year EPS growth and 30.6% 5-year EPS CAGR maintain credible momentum. The continuity between historical earnings growth of 26.2% and forward 28.2%-30.6% is a green flag — no heroic acceleration required. Valuation: P/E of 40.39x appears elevated in isolation but the PEG of 1.32 (computed against the 30.6% 5-year growth rate) shows the market is paying only 1.32x the growth rate — modestly above the 1.0x 'fair value' threshold and dramatically below the 4.59x industry average. If the 28.2% next-year EPS growth materializes, forward P/E drops to approximately 31.5x, and on year-5 earnings at the 30.6% CAGR, the implied P/E is roughly 9-10x — deep value on a time-horizon basis. Health: Debt-to-Equity of 1.41 (66% above industry average of 0.85) is the primary concern, but $20.05B annual FCF provides substantial cover — debt service capacity is unambiguous. Cash of $8.95B provides near-term liquidity. Price-to-Book of 33.03x is high but irrelevant for a patent-franchise company where intangible value dominates.
News Sentiment
Eli Lilly is on a roll — and not just because of its blockbuster weight-loss drugs. The pharmaceutical giant is quietly building one of the most diversified drug pipelines in the industry, and Wall Street is taking notice. The company just scored a major win with the FDA, which expanded the approval of its cancer drug Jaypirca (pirtobrutinib) to treat previously untreated patients with a type of blood cancer called CLL/SLL — making it the only drug of its kind with that first-line green light. That matters because it gives Lilly a unique selling point that competitors simply can't match right now. But that's not all. Lilly is also expanding its fight against cancer into new territory — the company announced progress with a pancreatic cancer drug, one of the hardest cancers to treat, signaling that its oncology ambitions are serious. Meanwhile, the company extended its drug discovery partnership with Gate Bioscience in a deal worth more than $870 million, deepening a pipeline that analysts say could unlock another massive growth wave beyond the weight-loss category. Perhaps most intriguing: analysts are already predicting Lilly could become the next $2 trillion company — joining an exclusive club that currently includes only Apple and Nvidia. The lone skeptical voice in the room warns that Lilly's valuation premium may not be fully justified relative to pharma peers, but with extraordinary profitability, a PEG ratio showing it's actually cheaper than rivals on a growth-adjusted basis, and a news flow that keeps delivering positive surprises, the bull case remains firmly intact.
Risk Assessment
Primary risk: GLP-1 pricing/coverage pressure (MFN pricing, PBM negotiations, 72%→60% coverage trajectory) could trigger simultaneous EPS miss + multiple compression at P/E 40.39x — a 10% EPS miss combined with a 3-turn P/E de-rating would imply ~20% stock decline. Mitigation: $20.05B FCF provides buffer; pipeline diversification (oncology, cardiometabolic) reduces single-franchise dependence; 30.6% EPS CAGR provides substantial headroom before concern materializes. Secondary risk: Debt-to-Equity 1.41 (66% above industry 0.85) limits balance sheet flexibility if GLP-1 revenues disappoint. Mitigation: FCF covers debt service comfortably; leverage is declining trend given FCF generation pace. Technical risk: Analyst target reduced to $1,328.33, leaving only 11.7% upside to consensus — if the stock continues to appreciate toward the target, the risk/reward shrinks further and position sizing should be re-evaluated. Stop-loss at $1,098 (approximately 7.6% below entry midpoint $1,176.50) limits downside to a level where the fundamental thesis would require material revision (below prior strong support zone and implying P/E de-rating below 37x — a level at which the growth premium would be questioned).
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is LLY a halal stock?
Yes, Eli Lilly and Company (LLY) is halal-compliant per AAOIFI standards as of the latest quarterly review.
What is Plutrex's AI rating for LLY?
Eli Lilly and Company (LLY) has a Plutrex AI rating of 85.0/100 with a Strong Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is LLY a good investment?
According to Plutrex AI, LLY has a Strong Buy rating (85.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in LLY?
US stocks like LLY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in LLY?
Plutrex AI identifies the main risks for LLY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.